Screening for cardiovascular safety: A structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 7, 2006, Pages 2339-2352

  Kym, Philip R ^a,b   Souers, Andrew J ^a,b   Campbell, Thomas J ^a,c   Lynch, John K ^a,b   Judd, Andrew S ^a,b   Iyengar, Rajesh ^a,b   Vasudevan, Anil ^a,b   Gao, Ju ^a,b   Freeman, Jennifer C ^a,b   Wodka, Dariusz ^a,b   Mulhern, Mathew ^a,b   Zhao, Gang ^a,b   Wagaw, Seble H ^a,d   Napier, James J ^a,d   Brodjian, Sevan ^a,b   Dayton, Brian D ^a,b   Reilly, Regina M ^a,b   Segreti, Jason A ^a,c   Fryer, Ryan M ^a,c   Preusser, Lee C ^a,c   Reinhart, Glenn A ^a,c   Hernandez, Lisa ^a,c   Marsh, Kennan C ^a,c   Sham, Hing L ^a,b   Collins, Christine A ^a,b   Polakowski, James S ^a,c   more..

^a ABBOTT LABORATORIES   (United States)

^b Metabolic Disease Research   (United States)

^c Metabolic Disease Research ^*  (United States)

^d Process Chemistry

Author keywords

[No Author keywords available]

Indexed keywords

CHROMONE DERIVATIVE; INDAZOLE DERIVATIVE; MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE RECEPTOR 1 BLOCKING AGENT; N [1 (1,3 BENZODIOXOL 5 YLMETHYL)PIPERIDIN 4 YL] 6,7 DICHLORO 4 OXO 4H CHROMENE 2 CARBOXAMIDE; N [1 (1,3 BENZODIOXOL 5 YLMETHYL)PIPERIDIN 4 YL] 7 METHOXY 4 OXO 4H CHROMENE 2 CARBOXAMIDE; RECEPTOR BLOCKING AGENT; THIOBUTABARBITAL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASSAY; CELL LINE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RAT STRAIN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ANTI-OBESITY AGENTS; BLOOD PRESSURE; BRAIN; CARDIOVASCULAR SYSTEM; CELL LINE, TUMOR; CHROMONES; DOGS; INDAZOLES; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 33645693576     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0512286     Document Type: Article

References (24)

1. Saito, Y.; Nothacker, H.-P.; Civelli, O. Melanin-concentrating hormone receptor: An orphan receptor fits the key. Trends Endocrinol. Metab. 2000, 11, 299-303.
2. Schwartz, M. W.; Woods, S. C.; Porte, D., Jr.; Selley, R. J.; Baskin, D. G. Central nervous system control of food intake. Nature 2000, 404, 661-671.
3. Della-Zuana, O.; Presse, F.; Ortola, C.; Duhault, J.; Nahon, J. L.; Levens. N. Acute and chronic administration of melanin-concentrating hormone enhances food intake and body weight in Wistar and Sprague-Dawley rats. Int. J. Obesity 2002, 26, 1289-1295.
4. Gomori, A.; Ishihara, A.; Ito, M.; Mashiko, S.; Matsushita, H.; Yumoto, M.; Ito, M.; Tanaka, T.; Tokita, S.; Moriya, M.; Iwaasa, H.; Kanatani, A. Chronic intracerebroventricular infusion of MCH causes obesity in mice. Am. J. Physiol. Endocrinol. Metab. 2003, 284, E583-E588.
5. Ludwig, D. S.; Tritos, N. A.; Mastaitis, J. W.; Kulkarni, R.; Kokkotou, E.; Elmquist, J.; Lowell, B.; Flier, J. S.; Maratos-Flier, E. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin. Invest. 2001, 107, 379-386.
6. Shimada, M.; Tritos, N. A.; Lowell, B. B.; Flier, J. S.; Maratos-Flier, E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998, 396, 670-674.
7. Chen, Y.; Hu, C.; Hsu, C-K.; Zhang, Q.; Bi, C.; Asnicar, M.; Hsiung, H. M.; Fox, N.; Slieker, L. J.; Yang, D. D.; Heiman, M. L.; Sh, Y. Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinol. 2002, 143, 2469-2477.
8. Marsh, D. J.; Weingarth, D. T.; Novi, D. E.; Chen, H. Y.; Trumbauer, M. E.; Chen, A. S.; Guan, X.-M.; Jiang, M. M.; Feng, Y.; Camacho, R. E.; Shen, Z.; Frazier, E. G.; Yu, H.; Metzger, J. M.; Kuca, S. J.; Shearman, L. P.; Gopal-Truter, S.; MacNeil, D. J.; Strack, A. M.; MacIntyre, D. E.; Van der Ploeg, L. H. T.; Qian, S. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 3240-3245.
9. (a) Borowsky, B.; Durkin, M. M.; Ogozalek, K.; Marzabadi, M. R.; DeLeon, J.; Lagu, B.; Heurich, R.; Lichtblau, H.; Shaposhnik, Z.; Daniewska, I.; Blackburn, T. P.; Branchek, T. A.; Gerald, C.; Vaysse, P. J.; Forray, C. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nature Med. 2002, 8, 779-781.
10. (b) An orally active small molecule MCHr1 antagonist in an acute feeding model was reported in the following: Takekawa, S.; Asami, A.; Ishihara, Y.; Terauchi, J.; Kato, K.; Shimomura, Y.; Mori, M.; Murakoshi, H.; Kato, K.; Suzuki, N.; Nishimura. O.; Fujino, M. T-226296: A novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur. J. Pharmacol. 2002. 438, 129-135.
11. Kym, P. R.; Iyengar, R.; Souers, A. J.; Lynch, J. K.; Judd, A. S.; Gao, J.; Freeman, J.; Mulhern, M.; Zhao, G.; Vasudevan, A.; Wodka, D.; Blackburn, Ch.; Brown, J.; Che, J. L.; Cullis, C.; Lai, Su J.; LaMarche, M.; Marsilje, T.; Roses, J.; Sells, T.; Geddes, B.; Govek, E.; Patane, M.; Fry, D.; Dayton, B. D.; Brodjian, S.; Falls, D.; Brune, M.; Bush, E.; Shapiro, R.; Knourek-Segel, V.: Fey, T.; McDowell, C.; Reinhart, G. A.; Preusser, L. C.; Marsh, K.; Hernandez, L.; Sham, H. L.; Collins, C. A. Discovery and Characterization of Amino-piperidinecoumarin Melanin Concentrating Hormone Receptor 1 Antagonists. J Med. Chem. 2005, 48, 5888-5891.
12. Souers, A. J.; Gao, J.; Brune, M.; Bush, E.; Wodka, D.; Vasudevan, A.; Judd, A. S.; Mulhern, M.; Brodjian, S.; Dayton, B.; Shapiro, R.; Hernandez, L.; Collins, C. A.; Kym, P. R. Identification of 2-(4-benzyloxyphenyl)-N-[1-(2- pyrrolidin-1-yl-ethyl)-1H-indazol-6-y1]-acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity. J. Med. Chem. 2005, 48, 1318-1321.
13. Vasudevan, A.; LaMarche, M. J.; Blackburn, C.; Che, J. L.; Luchaco-Cullis, C. A.; Lai, S.; Marsilje, T. H.; Patane, M. A.; Souers, A. J.; Wodka, D.; Geddes, B.; Chen, S.; Brodjian, S.; Falls, D. H.; Dayton, B. D.; Bush, E.; Brune, M.; Shapiro, R. D.; Marsh, K. C.; Hernandez, L. E.; Sham, H. L.; Collins, C. A.; Kym, P. R.. Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 4174-4179.
14. Vasudevan, A.; Souers, A. J.; Freeman, J. C.; Verzal, M. K.; Gao, J.; Mulhern, M. M.; Wodka, D.; Lynch, J. K.; Engstrom, K. M.; Wagaw, S. H.; Brodjian, S.; Dayton, B.; Falls, D. H.; Bush, E.; Brune, M.; Shapiro, R. D.; Marsh, K. C.; Hernandez, L. E.; Collins, C. A.; Kym, P. R. Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 5293-5297.
15. Fryer R. M.; Preusser L. C.; Calzadilla S. C.; Hu Y.; Xu H.; Marsh K. C.; Cox B. F.; Lin C. T.; Gopalakrishnan M.; Reinhart G. A. (-)-(9S)-9-(3-Bromo-4- fluorophenyl)-2,3,5,6,7,9-hexahydrothieno-[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: Hemodynamic comparison to ZD-6169, WAY-133537 and nifedipine in the anesthetized canine. J Cardiovasc. Pharmacol. 2004, 44, 137-147.
16. Raheem, I. T.; Goodman, S. N.; Jacobsen, E. N. Catalytic asymmetric total syntheses of quinine and quinidine. J. Am. Chem. Soc. 2004, 126, 706-707.
17. Compounds were tested for % inhibition @ 10 μM in a standard panel of 78 receptors and ion channels offered from CEREP (www.cerep.com).
18. Screening of 130 MCHr1 antagonists for hERG blockade using cell-based dofetilide binding assays showed no correlation between hERG blockade and hemodynamic effects in vivo.
19. Polakowski, J. S.; Segreti, J. A.; Cox, B. F.; Hsieh, G. C.; Kolasa, T.; Moreland, R. B.; Brioni, J. D. Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clin. Exp. Pham. Phys. 2004, 31, 837-841.
20. Reinhart G. A.; Fryer R. M.; Osinski, M. A.; Polakowski, J. S.; Cox, B. F. Gintant, G. A. Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forward. Curr. Opin. Chem. Biol. 2005, 9, 1-8.
21. For studies in anesthetized dogs, the minimum pressure limit tolerated was 50% reduction in the MAP relative to vehicle treated animals. For studies in inactin-anesthetized rats, the minimum pressure limit tolerated was 70 mmHg. This minimum pressure level was implemented to ensure a functional cardiovascular system for the collection of the end-of-study blood sample used for drug plasma level determinations.
22. Souers, A. J.; Gao, J.; Wodka, D.; Judd, A. S.; Mulhern, M. M.; Napier, J. J.; Brune, M. E.; Bush, E. N.; Brodjian, S. J.; Dayton, B. D.; Shapiro, R.; Hernandez, L. E.; Marsh, K. C.; Sham, H. L.; Collins, C. A.; Kym, P. R. Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Bioorg. Med. Chem. Lett. 2005, 15, 2752-2757.
23. Ma, V. V.; Balan, C.; Tempest, P. A.; Hulme, C.; Bannon, T. Abstract of Papers, 224th National Meeting of the American Chemical Society, Boston, MA.; American Chemical Society: Washington, DC, 2002; Abstract MEDI-343.
24. Fry, D.; Dayton, B.; Brodjian, S.; Ogiela, C.; Sidorowicz, H.; Frost, L. J.; McNally, T.; Reilly, R. M.; Coffins, C. A. Characterization of a neuronal cell line expressing native human melanin-concentrating hormone receptor 1 (MCHr1). Int. J. Biochem. Cell-Biol. 2006, in press.